Interstitial Lung Disease Trial, Recruiting (NCT06655090)

Interstitial Lung Disease Trial, Recruiting NCT06655090 Sponsor: Dai Huaping Condition: Interstitial Lung Disease

Printed from Voxsanity (voxsanity.com.au) — NCT06655090 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Interstitial Lung Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with a lung condition called interstitial lung disease (ILD), which is a group of conditions that cause scarring or inflammation in the lungs

Who may not be able to join:

You do not have a chest CT scan (a detailed X-ray image of your chest) available
You have chosen not to take part in the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Huaping Dai, M.D. Ph.D., China-Japan Friendship Hospital

Phone: 0086-10-84206271

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06655090

Sponsor: Dai Huaping

Phase: Not Applicable

Status: Recruiting

Condition: Interstitial Lung Disease

Trial contact: 0086-10-84206271

More information: https://clinicaltrials.gov/study/NCT06655090

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with a lung condition called interstitial lung disease (ILD), which is a group of conditions that cause scarring or inflammation in the lungs

Who may not be able to join:

You do not have a chest CT scan (a detailed X-ray image of your chest) available
You have chosen not to take part in the study

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Dai Huaping

Registry

ClinicalTrials.gov

Start date

1 December 2021

Est. completion

30 November 2024

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Clinical diagnostic protocol of ILD tissue biopsy; Predict model; Severity of fibrosis in HRCT assessed by AI system in patients with ILD; F-ILD cohort; Important molecular targets and biomarkers identified by multi-omics

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov